Rethinking Launch Strategy: Lessons from Early-Stage Oncology and IO Innovation

Session details:

As pharma companies push innovation into earlier stages of disease, traditional commercialization models are being stress-tested. In this session, Katy Miller, Global Franchise Head of IO & GI Cancer at AstraZeneca, shares how her team is adapting launch strategy for a new wave of IO treatments that can transform care for patients in the neoadjuvant and adjuvant settings. Drawing on AstraZeneca’s leadership in IO, trial innovation, and perioperative design, along with her cross-functional experience at a global and market level, she will offer strategic insights that apply well beyond oncology - aligning commercial and clinical teams earlier in development; engaging a broader range of health professionals involved in multi-disciplinary care teams; navigating changing endpoints and value frameworks; and building launch plans around combination therapies and biomarker-led precision.

Key takeaways from this presentation are as follows:

• What early-stage IO trials mean for the future of drug launches
• How novel combinations and personalized approaches are reshaping value strategy
• Why commercial teams must engage earlier - and differently - to stay ahead